Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
- 1 August 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 384 (9943), 591-598
- https://doi.org/10.1016/s0140-6736(14)61212-5
Abstract
No abstract availableFunding Information
- Swedish Heart-Lung Foundation (grant 20041151)
- Swedish Research Council (grants 2007-5942 and 2010-1078)
This publication has 44 references indexed in Scilit:
- Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling studyBMC Public Health, 2012
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidanceBMJ, 2008
- Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 2007
- Cost-Effectiveness Analysis of Hypertension Guidelines in South AfricaCirculation, 2005
- Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular riskThe Lancet, 2005
- Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)BMJ, 2004
- The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertensionJournal of Hypertension, 2003
- Selection of thrombolytic therapy for individual patients: Development of a clinical modelAmerican Heart Journal, 1997